The Value Line Investment Survey (Part 3 - Ratings & Reports) 2008 George Rho - Abstracts

The Value Line Investment Survey (Part 3 - Ratings & Reports) 2008 George Rho
TitleSubjectAuthors
Affymetrix Inc.(stock price appreciation potential)Business, generalGeorge Rho
Albany Molecular.(stock price appreciation potential)(Albany Molecular Research, Inc.)(Analyst report)Business, generalGeorge Rho
Boston Scientific.(stock price appreciation potential)Business, generalGeorge Rho
DENTSPLY Internat'l.(stock price appreciation potential)Business, generalGeorge Rho
Forest Labs.(stock price appreciation potential)(Forest Laboratories Inc.)(Analyst report)Business, generalGeorge Rho
Genomic Health.(stock price appreciation potential)Business, generalGeorge Rho
Gilead Sciences.(stock price appreciation potential)(Analyst report)Business, generalGeorge Rho
Illumina, Inc.(stock price appreciation potential)Business, generalGeorge Rho
ImClone Systems.(stock price appreciation potential)(Analyst report)Business, generalGeorge Rho
Lilly (Eli) and Co.(stock price appreciation potential)(Analyst report)Business, generalGeorge Rho
Medtronic Inc.(stock price appreciation potential)Business, generalGeorge Rho
Mentor Corp.(stock price appreciation potential)Business, generalGeorge Rho
Par Pharm.(stock price appreciation potential)(Par Pharmaceutical Companies Inc.)(Analyst report)Business, generalGeorge Rho
Schein (Henry) Inc.(stock price appreciation potential)Business, generalGeorge Rho
Schering-Plough.(stock price appreciation potential)(Analyst report)Business, generalGeorge Rho
Sepracor, Inc.(stock price appreciation potential)(Analyst report)Business, generalGeorge Rho
Stryker Corp.(stock price appreciation potential)Business, generalGeorge Rho
Valeant Pharmac.(stock price appreciation potential)(Valeant Pharmaceuticals)(Analyst report)Business, generalGeorge Rho
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.